HBc-Derived Antimicrobial Peptides for Drug-Resistant Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing problem of drug-resistant pathogens due to extensive use of traditional antibiotics necessitates the development of new antibiotics with a different mode of action, as existing treatments are ineffective against resistant strains.
Innovation Solution
The use of antimicrobial peptides derived from the arginine-rich carboxy-terminal region of the hepatitis B virus core protein (HBc), specifically peptides like HBc147-183, which exhibit broad-spectrum antimicrobial activity by binding to bacterial membranes and intracellular components, disrupting bacterial growth and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used extensively, then bacterial infections can be treated effectively, but drug-resistant pathogens emerge
Solution Approach 1:
The patent changes the fundamental parameters of antibiotic action by using peptides with amphipathic structures and positive charges that interact with bacterial membranes through electrostatic and hydrophobic forces, rather than relying on traditional antibiotic mechanisms that bacteria have developed resistance against
Solution Approach 2:
The antimicrobial peptides combine hydrophobic and hydrophilic regions in an amphipathic structure, creating a composite molecular architecture that enables simultaneous interaction with both the hydrophobic membrane core and hydrophilic membrane surface, achieving effective membrane disruption
2Reliability
If new antimicrobial peptides are developed, then effectiveness against drug-resistant pathogens improves, but understanding of mechanism of action is limited
Solution Approach 1:
The patent segments the complex antimicrobial mechanism into distinct functional components: (1) electrostatic interaction between positive peptide charges and negative bacterial membrane surfaces, (2) hydrophobic insertion of nonpolar peptide regions into the membrane core, and (3) membrane disruption leading to cell death. This segmentation enables systematic study and understanding of each mechanism component
3Reliability
If peptides with high antimicrobial activity are designed, then bactericidal effect increases, but potential toxicity to human cells may increase
Solution Approach 1:
The patent applies local quality differentiation by designing peptides with specific spatial distribution of charged and hydrophobic residues, where the amphipathic structure concentrates antimicrobial activity at the bacterial membrane interface while minimizing interaction with human cells through selective binding to bacterial membrane components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HBc-derived peptides demonstrate significant bactericidal activity against both drug-resistant and sensitive bacterial strains, including Staphylococcus aureus and Klebsiella pneumoniae, with minimal toxicity to human cells, offering a promising therapeutic option for microbial infections.
Implementation Method 1
they contain 10-50 amino acids, with an overall positive charge and an amphipathic structure. It is well known that most AMPs can directly bind to bacteria membrane and kill them by disrupting membrane
Implementation Method 2
amphipathic structure. It is well known that most AMPs can directly bind to bacteria membrane and kill them by disrupting membrane
Data Source
AI summary
A pharmaceutical composition comprising: (a) an isolated peptide, wherein the peptide includes three or four arginine-rich domains (ARDs) from the carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an anti-microbial activity; and (b) a pharmaceutically acceptable carrier.